Cosmos Health Purchases an Additional $300,000 in Ethereum Under Its $300 Million Digital Assets Facility; Total Investment Reaches $1.8 Million

Rhea-AI Summary

Cosmos Health (NASDAQ:COSM) announced on October 13, 2025 that it purchased an additional $300,000 of Ethereum (ETH), bringing its total ETH holdings to $1.8 million. The purchase was executed under the company’s existing $300 million digital assets facility, which the company says supports its strategy to diversify holdings via strategic digital asset investments. Management reiterated commitment to continue the acquisition program under the financing facility.

CHICAGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has purchased an additional $300,000 worth of Ethereum (ETH), increasing its total investment in ETH to $1.8 million.

This latest purchase was made under Cosmos Health’s previously announced $300 million digital assets facility, which supports the Company’s ongoing strategy to diversify its portfolio through strategic digital asset investments.

Greg Siokas, CEO of Cosmos Health, stated: “We have continued to increase our Ethereum holdings following last week’s purchase, bringing our total investment in ETH to $1.8 million. We remain committed to accelerating our acquisition program under our $300 million financing facility.”

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise

Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com

FAQ

How much Ethereum did Cosmos Health (COSM) buy on October 13, 2025?

Cosmos Health purchased $300,000 of Ethereum on October 13, 2025.

What are Cosmos Health's total Ethereum holdings after the October 13, 2025 purchase?

After the purchase, Cosmos Health's total investment in Ethereum is $1.8 million.

Under which financing program did COSM make the October 2025 Ethereum purchase?

The purchase was made under Cosmos Health’s existing $300 million digital assets facility.

Does the October 13, 2025 ETH purchase by COSM indicate future buying plans?

Management said the company remains committed to accelerating its acquisition program under the $300 million facility, indicating potential further purchases.

How does the $300,000 ETH purchase affect COSM shareholders immediately?

The announcement reports an additional $300,000 crypto purchase and total ETH holdings of $1.8 million; no shareholder action or dilution was announced.

Where can investors find more details about Cosmos Health's digital assets facility and ETH holdings?

Investors should consult Cosmos Health investor communications and SEC filings for full details on the $300 million digital assets facility and disclosed crypto holdings.